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Melioidosis, an infection due to Burkholderia pseudomallei, is endemic in southeast Asia and northern
Australia. We reviewed our experience with meropenem in the treatment of severe melioidosis in 63 patients
over a 6-year period. Outcomes were similar to those of ceftazidime-treated patients (n  153) despite a
deliberate selection bias to more-unwell patients receiving meropenem. The mortality among meropenem-
treated patients was 19%. One patient had a possible drug fever associated with the use of meropenem. We
conclude that meropenem (1 g or 25 mg/kg every 8 h intravenously for >14 days) is an alternative to
ceftazidime and imipenem in the treatment of melioidosis. The use of meropenem may be associated with
improved outcomes in patients with severe sepsis associated with melioidosis.
Melioidosis is endemic to southeast Asia and northern Aus-
tralia. Despite improvements in antibiotic therapy, it is still
associated with a high mortality (20, 21). The causative organ-
ism, Burkholderia pseudomallei is resistant to penicillins, ami-
noglycosides, and rifamycins and relatively insensitive to quin-
olones and macrolides; thus, therapeutic options are limited.
Despite the excellent in vitro activity of meropenem, there is
little published clinical data regarding the use of meropenem
in the treatment of melioidosis. A clinical trial compared the
use of the related carbapenem imipenem to ceftazidime in 214
patients with confirmed severe melioidosis in Thailand (15).
However, despite a reduction in the number of treatment fail-
ures in the imipenem arm of the study, a possibly subjective
endpoint in this open-label trial, there were no significant
differences in mortality. However, this trial was underpowered
due to the withdrawal of pharmaceutical support.
Carbapenem antibiotics have some theoretical benefits over
ceftazidime in that they are more active in vitro (10, 16, 17, 23),
demonstrate a postantibiotic effect (19), and are associated
with decreased endotoxin release (14). Thus, carbapenem an-
tibiotics may be of benefit in patients critically ill with melioid-
osis, a group with a historically high mortality. Furthermore, its
broad spectrum is attractive for empirical coverage of common
causes of community-acquired sepsis at our institution.
Based on these considerations, we have been using mero-
penem for the treatment of selected patients with melioidosis,
including critically ill patients with severe sepsis, since 1997.
We recently reported an association between the use of gran-
ulocyte colony-stimulating factor and a dramatic fall in mor-
tality from septic shock due to melioidosis (4). However, we
acknowledged that our use of meropenem may have con-
founded this analysis. In this series, we report our experience
with meropenem, comparing outcomes with those of patients
treated with ceftazidime.
MATERIALS AND METHODS
The Royal Darwin Hospital is a 300-bed referral center based in Darwin,
Australia, and receives patients from the Top End of the Northern Territory, an
area where melioidosis is endemic. Since 1989, we have prospectively docu-
mented clinical details on all cases of melioidosis seen in the Top End (5).
Meropenem has been used in selected cases of melioidosis at our institution
since August 1997. We advocate the use of meropenem at 25 mg/kg (up to 1 g)
every 8 h with trimethoprim/sulfamethoxazole (8/40 mg/kg, or up to 320/1,600 mg
every 12 h), with a total duration of intensive intravenous therapy of at least 14
days, followed by an extended course of oral eradication therapy. For patients
with impaired renal function except patients on hemofiltration (6), the dose of
meropenem was adjusted by altering both dose and interval according to estab-
lished guidelines (22).
For this study, clinical details were reviewed for patients treated for melioid-
osis since August 1997. For this study, we defined two groups; the meropenem
group comprised patients that received meropenem as part of their therapy for
melioidosis (including patients switched from ceftazidime), and the ceftazidime-
only group received ceftazidime as treatment and excluded patients that received
carbapenems during their therapy course.
Indications for the use of meropenem included patients with critical illness
(including severe sepsis) admitted to intensive care for management, clinical
failure, or intolerance to ceftazidime and relapse following therapy with cefta-
zidime. Other patients received ceftazidime plus trimethoprim/sulfamethoxazole
as initial therapy. We specifically sought details of possible adverse events,
treatment failure requiring a change in therapy, and disease relapse.
At our institution, patients were referred to the intensive care unit for man-
agement of severe sepsis, respiratory failure due to poor gas exchange or poor
conscious state, or renal replacement therapy for acute and/or chronic renal
failure. Standard management of patients with severe sepsis, defined by standard
criteria (1), including melioidosis, included the routine use of granulocyte colo-
ny-stimulating factor (since 1998) (18), early goal-directed resuscitation strate-
gies similar to those previously published (12), early enteral feeding, the use of
sedation protocols (3) (all since 1998), and physiological dose steroids (2) (since
2001).
Statistical tests were performed with Intercooled Stata 7.0 (College Station,
Tex.). For comparisons of proportions, Fisher’s exact test was used. For com-
parisons of nonparametric distributions, the Mann-Whitney U test was used.
Statistical differences were deemed significant at the 0.05 level.
Approval to review data for this study was given by the Human Research
Ethics Committee of the Department of Health and the Menzies School of
Health Research.
RESULTS
During the period from 1 August 1997 to 31 July 2003, 217
patients were treated for melioidosis at our institution. Mero-
* Corresponding author. Mailing address: Menzies School of Health
Research, Charles Darwin University, P.O. Box 41096, Casuarina NT
0811, Northern Territory, Darwin, Australia. Phone: 61889228196.
Fax: 61889275187. E-mail: bart@menzies.edu.au.
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penem was administered to 63 patients; 5 patients relapsed and
were retreated, giving a total of 68 admissions. Among the
patients treated with meropenem, 19% died (8 deaths attrib-
utable to melioidosis and 4 to unrelated causes: one each to
suicide, nonmelioidosis sepsis, heart failure, and metastatic
carcinomatosis).
In comparison, ceftazidime was used exclusively in 154 pa-
tients (including 11 patients readmitted due to relapse; total,
165 admissions). Among these patients, the mortality rate was
18% (16 attributable to melioidosis and 12 due to underlying
disease). The characteristics of the patients are detailed in
Table 1. Higher proportions of patients treated with mero-
penem had severe sepsis and bacteremia (P  0.001), reflect-
ing our selection criteria for the use of this antibiotic. In the
subgroup with severe sepsis, the use of meropenem was asso-
ciated with a lower mortality than ceftazidime (25% versus
76%, P  0.001).
Of the 68 episodes where meropenem was used, the majority
began on meropenem as initial therapy (n  48). The reasons
for the initial choice of meropenem were severe sepsis, includ-
ing septic shock (n  28), central nervous system infection (n
 4), relapsed disease following apparently successful treat-
ment with ceftazidime (n  8), and other clinical reasons (n 
8), including a single patient from whom a ceftazidime-resis-
tant strain was isolated. In addition, ceftazidime was used ini-
tially in 20 admissions where there was a subsequent change to
meropenem, 17 for worsening clinical condition on treatment
and 3 for suspected adverse reactions (rash in 2 and thrombo-
cytopenia in 1). Ceftazidime was used subsequent to the course
of meropenem in 12 episodes, in 9 cases once the patient’s
clinical status had stabilized, and to facilitate discharge for
home therapy with continuous ceftazidime infusion via elasto-
meric pump. One patient was treated initially with imipenem
and later changed to meropenem.
There were one probable and three possible adverse events
associated with the use of meropenem. One patient had ongo-
ing fever and neutropenia that resolved once therapy had been
changed to a ceftazidime-based regimen. One patient had sei-
zures associated with intracranial infection that occurred both
prior and subsequent to the commencement of meropenem
treatment. One patient had a rash while on meropenem and
trimethoprim/sulfamethoxazole that resolved after the antibi-
otics were changed to chloramphenicol and doxycycline. One
further patient had thrombocytopenia which persisted follow-
ing cessation of meropenem; therapy with meropenem was
later recommenced once his thrombocytopenia had resolved
without incident. No patients required a change in therapy due
to abnormal liver function with meropenem.
No strains that had primary resistance to meropenem were
isolated. A thoracotomy and change in therapy from mero-
penem to ceftazidime in one patient was prompted by an
increasing MIC of meropenem (0.75 to 4 mg/liter), but this
strain remained sensitive.
This series included 21 patients treated with granulocyte
colony-stimulating factor, 19 of whom have been reported pre-
viously (4).
DISCUSSION
Although meropenem has been used for the treatment of
melioidosis in isolated cases (8, 9, 13), this observational study
is the first to demonstrate positive outcomes in melioidosis
with meropenem. Although we are not able to quantify any
benefits in this observational study, the overall mortality rate
that we observed is similar to that for ceftazidime-treated pa-
tients despite a deliberate selection bias toward patients with
more severe infections to receive meropenem. More specifi-
cally, the mortality in those with severe sepsis was lower with
meropenem.
Despite its expense, meropenem provides practical and the-
TABLE 1. Characteristics of patients
Characteristic Meropenem-treatedpatients
Ceftazidime-treated
patients
Odds ratio (95%
confidence interval) P
No. patients 63 154
Mean age, yrs (range) 50 (6 mo–73 yr) 49 (2–78 yr) NSa
No. (%) male 46 (73%) 114 (74) NS
No. of deaths
Infection 8 (13%) 16 (10) 1.3 (0.52, 3.0) NS
All causes 12 (19) 28 (18) 1.1 (0.51, 2.2) NS
No. of diabetic patients (%) 30 (48) 53 (34) 1.7 (0.95, 3.1) 0.09
No. of patients with renal failure (%) 6 (10) 12 (8) 1.2 (0.46, 3.4) NS
No. (%) of episodesb 68 165
Pneumonia 40 (59) 74 (44) 1.8 (0.99, 3.1) 0.06
Genitourinary infection 6 (9) 29 (18) 0.45 (0.18, 1.1) 0.11
Central nervous system infection 4 (6) 2 (1.2) 5.1 (—)d 0.06
Severe sepsis 28 (41) 21 (13) 4.8 (2.5, 9.2) 0.001
Mortality from severe sepsis 7 (25) 16 (76) 0.10 (0.03, 0.38) 0.001
Received G-CSFc 21 (31) 0 — 0.001
Received physiological dose of corticosteroidsc 5 (7) 0 — 0.002
Bacteremic 51 (75) 65 (39) 4.6 (2.5, 8.6) 0.001
Mortality from bacteremia 10 (20) 16 (25) 1.6 (0.70, 3.7) NS
a NS, not significant.
b As a proportion of the total number of episodes (including readmissions for relapse).
c Received granulocyte colony-stimulating factor (G-CSF; commenced 1998) and corticosteroids (commenced 2001) for septic shock.
d —, 95% confidence intervals not calculable.
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oretical advantages over both ceftazidime and imipenem. Un-
like imipenem, meropenem is not associated with seizures, a
particular concern for patients with renal failure and patients
with intracerebral infection. In addition, meropenem has a
more favorable dosing schedule (three versus four times per
day) than imipenem. Compared to ceftazidime, carbapenem
antibiotics have a lower MIC for B. pseudomallei (10, 16, 23)
and a faster time-kill profile (17), including resistant isolates
(16). Additionally, carbapenems demonstrate a postantibiotic
effect not seen with ceftazidime (19) and are associated with
decreased endotoxin release (14). These factors may be impor-
tant in critically unwell patients requiring more rapid control of
high bacterial loads and proinflammatory dysregulation. Al-
though a previous clinical trial in which imipenem was com-
pared to ceftazidime failed to find any mortality benefit (15),
we observed a significant reduction in mortality among pa-
tients with severe sepsis. This may reflect an interaction be-
tween other intensive-care interventions in our developed-
world context and the use of meropenem.
Many other factors are likely to contribute to the low mor-
tality observed in this study compared to those published pre-
viously (7, 11, 15), including early diagnosis and treatment, the
availability of resources for intensive-care management, the
use of granulocyte colony-stimulating factor, and evidence-
based protocols for severely septic patients. Our evidence also
supports the use of ceftazidime in milder infections and to
complete the intensive phase in an outpatient setting, which is
not possible with meropenem due to its poor stability.
In this study, we noted that meropenem is associated with
outcomes at least as good as those obtained with ceftazidime.
Theoretical considerations support our data, which suggest
that its use may be associated with improved outcomes in
patients with severe sepsis in a setting where other intensive-
care interventions have been optimized. This hypothesis de-
serves further scrutiny in appropriately powered randomized
controlled trials. Meanwhile, this work supports Australian
guidelines listing meropenem as an alternative first-line agent
in the treatment of severe melioidosis (5, 22).
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